AUTHORS
Zhirong Chai, B.S., Zhijian Wu, MD, PhD2, Liang Zheng, PhD3, Xiaxin Dong, M.S.4, Esteban M. Dominguez, DDS5, Michael J Soares, PhD6, X. Long Zheng, MD, PhD7
AFFILIATIONS
1 The University of Kansas Medical Center, Kansas City, Kansas, United States
2 The University of Kansas Medical Center, Kansas City, Kansas, United States
3 The University of Kansas Medical Center, Kansas City, Kansas, United States
4 The University of Kansas Medical Center, Kansas City, Kansas, United States
5 The University of Kansas Medical Center, Kansas City, Kansas, United States
6 The University of Kansas Medical Center, Kansas City, Kansas, United States
7 The University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background: Preeclampsia (PE) is a serious pregnancy associated complication, characterized by hypertension, proteinuria, fetal growth restriction, and increased perinatal morbidity and mortality. Abnormal placentation and maternal endothelial dysfunction may contribute to the pathogenesis of PE. Patients with PE show significantly increased levels of plasma von Willebrand factor (VWF) and reduced plasma ADAMTS13, a metalloprotease that cleaves VWF. However, the causative role of the VWF/ADAMTS13 imbalance in pathogenesis and outcome of PE has not been established.
Objective: We aim to determine if systemic VWF/ADAMTS13 imbalance contributes to the onset and progression of PE in rat models and its underlying molecular mechanism.
Methods: Two complementary rat models were established and characterized. In the first model, PE was induced in pregnant wild-type (WT) rats following daily (75 mg/kg/day) administration of Nω-nitro-L-arginine methyl ester (L-NAME), a non-selective inhibitor of nitric oxide synthases, or vehicle. In the second model, maternal blood pressure, urinary protein/creatinine ratio, and pregnancy outcome were determined in WT and Adamts13-/- rats. Furthermore, renal tissue histology, fetal and placental weights, and fetal resorption rates were determined. Plasma VWF multimer distribution and ADAMTS13 activity were also analyzed with multimer analysis and FRETS-VWF73, respectively. Placental tissues were examined by immunohistochemistry for VWF-, fibrin-, and platelet-rich thrombotic deposits. Immunofluorescence staining for cytokeratin 7 (CK7), CD31, and α-smooth muscle actin (α-SMA) was used to evaluate invasive trophoblast distribution and spiral artery remodeling.
Results: L-NAME-treated pregnant rats developed significantly elevated blood pressure, proteinuria, and histological evidence of renal injury, consistent with the development of PE. The animals exhibited severe fetal growth restriction and an increased fetal resorption. L-NAME treated pregnant rats showed a markedly increased accumulation of ultra large VWF (ULVWF) multimers but reduced circulating ADAMTS13 levels. Immunostaining demonstrated abundant VWF-, fibrin-, and platelet-rich deposits at the uteroplacental interface, consistent with placental thrombotic injury. Independently, Adamts13-/- pregnant rats developed higher blood pressure in late gestation than WT controls.Adamts13-/- pregnancies were characterized by fetal growth restriction, increased fetal resorption, and proteinuria. ULVWF multimer levels were more dramatically increased in late gestation in Adamts13-/- rats in comparison to WT rats. Adamts13-/- placental tissues showed persistent CD31-positive endothelial cells adjacent to the CK7-positive trophoblasts and retained α-SMA-positive smooth muscle layers surrounding the spiral arteries, suggesting impaired trophoblast-mediated endothelial cell replacement and incomplete spiral artery remodeling.
Conclusions: We have successfully established two different PE models in pregnant rats: L-NAME-induced PE in WT rats and spontaneous PE in Adamts13-/- rats. Both rat models demonstrate increased accumulation of plasma ULVWF and placental tissue deposition of VWF, fibrin, and platelets at the uterine-placental interface, as well as impaired trophoblast invasion and spiral arteriole remodeling. These results support the causative role of ADAMTS13/VWF imbalance in pathogenesis of PE. Thus, targeting the ADAMTS13/VWF axis may represent a potential novel therapeutic for PE.
Abbreviation: PE, preeclampsia; ULVWF, ultra-large von Willebrand factor; WT, wild type; ADAMTS13, A disintegrin and metalloprotease with thrombospondin type 1 repeats, 13.
DISCLOSURES
Zhirong Chai, B.S.: No relevant conflicts of interest to declare.